Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Single-dose, Double-blind, Double-dummy, Four-period, Four-treatment Crossover Pivotal Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) (of Macleods Pharmaceuticals Ltd.) to Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) (Distributed by Teva Pharmaceuticals USA, Inc.) in Adult Patients With Stable Mild Asthma

NCT06618105 is registered in ClinicalTrials.gov with Macleods Pharmaceuticals Ltd as lead sponsor.

NCT NCT06618105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06618105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Single-dose, Double-blind, Double-dummy, Four-period, Four-treatment Crossover Pivotal Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) (of Macleods Pharmaceuticals Ltd.) to Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) (Distributed by Teva Pharmaceuticals USA, Inc.) in Adult Patients With Stable Mild Asthma
Lead sponsor
Macleods Pharmaceuticals Ltd
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 15, 2024
Completion date
May 31, 2025
Enrollment
144 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mild asthma